JP2014504270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504270A5 JP2014504270A5 JP2013537908A JP2013537908A JP2014504270A5 JP 2014504270 A5 JP2014504270 A5 JP 2014504270A5 JP 2013537908 A JP2013537908 A JP 2013537908A JP 2013537908 A JP2013537908 A JP 2013537908A JP 2014504270 A5 JP2014504270 A5 JP 2014504270A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- receptor
- fusion protein
- integrin
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 108020001507 fusion proteins Proteins 0.000 claims description 24
- 102000037865 fusion proteins Human genes 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 19
- 108020004414 DNA Proteins 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 15
- 108020003175 receptors Proteins 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 7
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims description 4
- 108091026890 Coding region Proteins 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 101150022345 GAS6 gene Proteins 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims 16
- 108010044426 integrins Proteins 0.000 claims 16
- 101000609473 Ecballium elaterium Trypsin inhibitor 2 Proteins 0.000 claims 7
- 102000000844 Cell Surface Receptors Human genes 0.000 claims 4
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 claims 1
- 108091008794 FGF receptors Proteins 0.000 claims 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 1
- 108091008553 MuSK receptors Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 108091005729 TAM receptors Proteins 0.000 claims 1
- 108050003126 conotoxin Proteins 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 108091058550 ω-conotoxin Proteins 0.000 claims 1
- KNJNGVKTAFTUFL-OCMUWRIYSA-N ω-conotoxin Chemical group N([C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1C(N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CSSC1)C(N)=O)=O)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1 KNJNGVKTAFTUFL-OCMUWRIYSA-N 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 description 3
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41135010P | 2010-11-08 | 2010-11-08 | |
| US61/411,350 | 2010-11-08 | ||
| PCT/US2011/059599 WO2012064658A1 (en) | 2010-11-08 | 2011-11-07 | Fusion proteins comprising an engineered knottin peptide and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079525A Division JP6535361B2 (ja) | 2010-11-08 | 2017-04-13 | 改変ノッチンペプチドを含む融合タンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504270A JP2014504270A (ja) | 2014-02-20 |
| JP2014504270A5 true JP2014504270A5 (enExample) | 2014-12-25 |
| JP6170435B2 JP6170435B2 (ja) | 2017-07-26 |
Family
ID=46051256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537908A Active JP6170435B2 (ja) | 2010-11-08 | 2011-11-07 | 改変ノッチンペプチドを含む融合タンパク質及びその使用 |
| JP2017079525A Active JP6535361B2 (ja) | 2010-11-08 | 2017-04-13 | 改変ノッチンペプチドを含む融合タンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079525A Active JP6535361B2 (ja) | 2010-11-08 | 2017-04-13 | 改変ノッチンペプチドを含む融合タンパク質及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10844106B2 (enExample) |
| EP (2) | EP3604549A1 (enExample) |
| JP (2) | JP6170435B2 (enExample) |
| AU (3) | AU2011326164B2 (enExample) |
| CA (1) | CA2817197C (enExample) |
| DK (1) | DK2638173T3 (enExample) |
| WO (1) | WO2012064658A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008045252A2 (en) * | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| DK2638173T3 (da) | 2010-11-08 | 2019-09-30 | Univ Leland Stanford Junior | Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf |
| WO2013078250A2 (en) | 2011-11-22 | 2013-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Cystine knot peptides that bind alpha-v-beta-6 integrin |
| WO2013177187A2 (en) | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
| WO2014063012A1 (en) | 2012-10-19 | 2014-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugated knottin mini-proteins containing non-natural amino acids |
| CN105189540A (zh) | 2012-12-10 | 2015-12-23 | 弗莱德哈钦森癌症研究中心 | 含脂质运载蛋白融合伴侣 |
| ES2665323T7 (es) * | 2012-12-14 | 2023-06-15 | Univ Leland Stanford Junior | Péptidos de AXL modificados y su uso en la inhibición de la señalización de AXL en terapia anti-metastásica |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| US11013814B2 (en) | 2017-03-16 | 2021-05-25 | Blaze Bioscience, Inc. | Cartilage-homing peptide conjugates and methods of use thereof |
| EP3180018B1 (en) * | 2014-08-12 | 2019-07-24 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein |
| US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| EP3313427A4 (en) * | 2015-06-26 | 2018-12-26 | Fred Hutchinson Cancer Research Center | Therapeutic peptides and methods of use thereof |
| JP6966424B2 (ja) | 2015-09-09 | 2021-11-17 | フレッド ハッチンソン キャンサー リサーチ センター | 軟骨ホーミングペプチド |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| JP7308505B2 (ja) * | 2016-01-08 | 2023-07-14 | マキシオン セラピューティクス リミテッド | 多様性を変化させた足場ドメインを有する結合メンバー |
| US10888603B2 (en) * | 2016-02-12 | 2021-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cancer cells expressing tumor-associated integrins |
| US10765625B2 (en) | 2016-03-15 | 2020-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Knottin-drug conjugates and methods of using the same |
| WO2018044234A1 (en) * | 2016-08-31 | 2018-03-08 | Nanyang Technological University | Cysteine-rich polypeptides and conjugates and methods of using the same |
| US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
| US10603358B2 (en) | 2017-01-10 | 2020-03-31 | Nodus Therapeutics | Combination tumor treatment with an integrin-binding-Fc fusion protein and immune stimulator |
| US11548923B2 (en) | 2017-01-18 | 2023-01-10 | Fred Hutchinson Cancer Center | Peptide compositions and methods of use thereof for disrupting TEAD interactions |
| EP3638290A4 (en) | 2017-06-15 | 2021-04-07 | Blaze Bioscience, Inc. | KIDNEY HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF |
| GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
| JP7221545B2 (ja) | 2017-07-24 | 2023-02-14 | ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー | ホスファチジルセリン標的化融合分子およびそれらの使用方法 |
| AU2018388583A1 (en) | 2017-12-19 | 2020-06-11 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
| US11235032B2 (en) | 2019-01-23 | 2022-02-01 | Massachusetts Institute Of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
| CN113661240B (zh) * | 2019-04-02 | 2024-11-05 | 伊莱利利公司 | 选择和检测结合肽的方法 |
| JP2022531191A (ja) * | 2019-04-29 | 2022-07-06 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 肝細胞増殖因子の操作された二量体断片を使用する眼の治療方法 |
| SG11202112129SA (en) * | 2019-05-22 | 2021-11-29 | Univ Leland Stanford Junior | Drug conjugates and methods of using same |
| AU2020357806A1 (en) * | 2019-09-30 | 2022-05-26 | The Board Of Trustees Of The Leland Stanford Junior University | Knottin-immunostimulant conjugates and related compositions and methods |
| US20230211001A1 (en) * | 2020-07-30 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Lysosomal Targeting Molecules Comprising Knottin Peptides And Related Compositions And Methods |
| MX2020012914A (es) * | 2020-11-27 | 2022-05-30 | Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese | Proteina andamio para la generacion de proteinas quimericas de union a antigeno. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468634A (en) | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6303749B1 (en) * | 1999-01-29 | 2001-10-16 | Amgen Inc. | Agouti and agouti-related peptide analogs |
| DE10053224A1 (de) * | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| EP1358211A2 (en) | 2001-01-31 | 2003-11-05 | Mount Sinai Hospital | Methods for regulating the kinase domain of ephb2 |
| GB0110430D0 (en) | 2001-04-27 | 2001-06-20 | Medical Res Council | Protein variants and uses thereof |
| NZ548828A (en) | 2004-01-20 | 2009-07-31 | Merus B V | Mixtures of binding proteins |
| US20060040325A1 (en) * | 2004-08-16 | 2006-02-23 | Medimmune, Inc. | Integrin antagonists with enhanced antibody dependent cell-mediated cytoxicity activity |
| US7674881B2 (en) | 2005-10-07 | 2010-03-09 | The University Of Chicago | Convergent synthesis of proteins by kinetically controlled ligation |
| US7666622B2 (en) * | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| EP2170395A1 (en) * | 2007-07-02 | 2010-04-07 | Wyeth LLC | Modulators of axl for use in treating bone disorders |
| CA2694488A1 (en) * | 2007-07-31 | 2009-02-05 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| WO2009097017A2 (en) * | 2007-09-18 | 2009-08-06 | The Jackson Laboratory | Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof |
| US8906356B2 (en) * | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| WO2010048588A2 (en) | 2008-10-23 | 2010-04-29 | Massachusetts Institute Of Technology | Directed engagement of activating fc receptors |
| US8329826B2 (en) | 2008-11-06 | 2012-12-11 | The Board Of Trustees Of The Leland Stanford Junior University | Surface modification of interpenetrating polymer networks |
| US8778888B2 (en) | 2009-11-06 | 2014-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use |
| JP5965322B2 (ja) | 2010-01-22 | 2016-08-03 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗転移療法におけるａｘｌシグナル伝達の阻害 |
| DK2638173T3 (da) * | 2010-11-08 | 2019-09-30 | Univ Leland Stanford Junior | Fusionsproteiner omfattende et manipuleret knottin-peptid og anvendelser deraf |
| US10350266B2 (en) * | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
-
2011
- 2011-11-07 DK DK11839687.8T patent/DK2638173T3/da active
- 2011-11-07 AU AU2011326164A patent/AU2011326164B2/en not_active Ceased
- 2011-11-07 US US13/883,216 patent/US10844106B2/en active Active
- 2011-11-07 JP JP2013537908A patent/JP6170435B2/ja active Active
- 2011-11-07 EP EP19180924.3A patent/EP3604549A1/en not_active Withdrawn
- 2011-11-07 WO PCT/US2011/059599 patent/WO2012064658A1/en not_active Ceased
- 2011-11-07 EP EP11839687.8A patent/EP2638173B1/en active Active
- 2011-11-07 CA CA2817197A patent/CA2817197C/en active Active
-
2016
- 2016-08-04 AU AU2016210712A patent/AU2016210712B2/en not_active Ceased
-
2017
- 2017-04-13 JP JP2017079525A patent/JP6535361B2/ja active Active
-
2018
- 2018-01-24 AU AU2018200587A patent/AU2018200587B2/en not_active Ceased
-
2020
- 2020-10-08 US US17/066,167 patent/US11498952B2/en active Active
-
2022
- 2022-11-14 US US18/055,297 patent/US12240882B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504270A5 (enExample) | ||
| Webster et al. | Brain penetration, target engagement, and disposition of the blood‐brain barrier‐crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1 | |
| US11891436B2 (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15) | |
| Reguera et al. | Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies | |
| RU2769470C2 (ru) | Рекомбинантные связывающие белки и их применение | |
| Ebos et al. | A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma | |
| Goodman et al. | Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors | |
| ES2662372T3 (es) | Dominios de unión dirigidos contra complejos GPCR:proteína G y usos derivados de los mismos | |
| Papo et al. | Antagonistic VEGF variants engineered to simultaneously bind to and inhibit VEGFR2 and α v β 3 integrin | |
| JP2021502063A5 (enExample) | ||
| EA201290525A1 (ru) | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения | |
| RU2018102798A (ru) | Антитела к фактору xi и способы их применения | |
| TW201906867A (zh) | 嵌合抗體免疫效應細胞接合物及其使用方法 | |
| JP2019514361A5 (enExample) | ||
| DE602005026219D1 (de) | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper | |
| CN110809580A (zh) | 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物 | |
| Arcangeli et al. | The Junctional Adhesion Molecule-B regulates JAM-C-dependent melanoma cell metastasis | |
| Bhaskar et al. | Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits | |
| US20150165065A1 (en) | Non-natural mic proteins | |
| Sun et al. | Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8 | |
| JP2014530001A5 (enExample) | ||
| Farrell et al. | The PfRCR complex bridges malaria parasite and erythrocyte during invasion | |
| Kim et al. | Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis | |
| EP1660517A4 (en) | ANTAGONISTS OF NOGO RECEPTOR | |
| CA3018427C (en) | Adenoviral coat protein derived delivery vehicles |